Teclistamab in the Treatment of Multiple Myeloma: Latest Updates from the 2023 EHA Annual Meeting

Abstract

As a promising novel immunotherapy modality, bispecific antibodies (BsAbs) are actively being evaluated in clinical trials for patients with hematological malignancies. Teclistamab is a T-cell-directed IgG4λ BsAb that recognizes B-Cell Maturation Antigen (BCMA) on target cells and CD3ε on T cells. As one of the promising BsAbs, teclistamab was granted orphan designations for the treatment of Multiple Myeloma (MM) in both the US and EU, the breakthrough-therapy designation for the treatment of relapsed/refractory (RRMM) by the FDA, and a Priority Medicines (PRIME) designation for the treatment of adult patients with MM who previously received ≥3 prior lines of therapy by the EMA. Recent evidence suggests that teclistamab exhibits promising efficacy and low toxicity for patients with Relapsed/Refractory Multiple Myeloma (RRMM), even at late stages. As a recently approved agent by both the FDA and the EU for adult patients with RRMM who previously received ≥3 prior lines of therapy, teclistamab is being investigated as monotherapy and in combination clinical studies in patients with MM. Here we provide an overview of the latest clinical data on teclistamab in MM presented at the 2023 European Hematology Association (EHA) annual meeting.